Financial Data and Key Metrics Changes - The company reported a 10% increase in revenue for Q4 2025, with organic revenue growth of 3% year-over-year, driven by positive price and volume [8][9] - Adjusted EBITDA for Q4 was $580 million, with adjusted EBITDA margins at 27.7%, reflecting year-over-year margin pressure primarily due to tariff impacts and commercial investments [8][9] - For the full year, adjusted EBITDA was approximately $2.1 billion, with an adjusted EBITDA margin of 27.4% and adjusted earnings per share of $3.34, up 2% year-over-year [10] Business Line Data and Key Metrics Changes - In the ITS segment, orders increased by 9% in Q4, with organic orders growing in low single digits and revenue up 11% year-over-year [12] - The PST segment saw Q4 orders up 6% year-over-year, with organic orders up 1%, and life science businesses delivered mid-teens organic order growth [14][15] - Adjusted EBITDA for PST was $127 million, up 19% year-over-year, with a margin of 30.4% [15][16] Market Data and Key Metrics Changes - The Americas region showed low single-digit organic order growth, while EMEA experienced a mid-single-digit decline, and Asia Pacific saw low double-digit growth driven by China [13] - The company noted a strong pipeline in the life sciences market, with good funnel and booking activity in both the U.S. and internationally [26] Company Strategy and Development Direction - The company is focused on enhancing its existing portfolio through disciplined M&A, with a robust acquisition pipeline and a strategic emphasis on recurring revenue initiatives [4][5] - The recent acquisition of Scinomix is aimed at advancing the life science strategy by combining complementary technologies [6] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about improving trends in the market, particularly in life sciences and general industrial sectors, while acknowledging ongoing challenges [27][30] - The company anticipates total revenue growth of 2.5% to 4.5% for 2026, with adjusted EBITDA expected to be in the range of $2.13 billion to $2.19 billion [17][18] Other Important Information - The company ended 2025 with a book-to-bill ratio above 1, indicating a strong order backlog [9] - Free cash flow for Q4 was $462 million, with total liquidity of $3.8 billion, maintaining a strong balance sheet [10] Q&A Session Summary Question: What sort of end market trajectory is embedded in the guidance? - Management indicated that the guidance assumes current market conditions continue without significant recovery, with life sciences showing sequential improvement [25][30] Question: Are there any end markets that you're specifically worried about this year? - Management noted that headwinds from RNG, electric vehicles, and photovoltaics are largely behind them, with positive trends in China [30][31] Question: Can you clarify the seasonality through the year? - Management expects Q1 organic growth to be roughly flat, with low single-digit growth anticipated for the remainder of the year [36] Question: What are the expectations for cost actions or productivity gains during 2026? - Management confirmed that the guidance includes productivity and cost actions, with proactive restructuring expected to yield savings [82][84] Question: Can you provide color on the acquisition opportunity set? - Management stated that the acquisition pipeline remains strong, primarily focused on bolt-on opportunities, with potential for larger acquisitions [54][55]